• Neurosense Therapeutics is trading 7.32% up in pre-market at $0.44 following HC Wainwright & Co. initiating coverage with a 'Buy' rating and an $8.00 price target.
  • The company also recently highlighted its redesigned, three-pronged PrimeC development strategy for ALS, aiming to accelerate potential approval and reduce costs.
  • A Health Canada filing for PrimeC is targeted for December 2026.